Read on Twitter
Preprint-ChAdOx1
trial in HIV(-) people in South Africa.
23/717 (3.2%) placebo & 19/750 (2.5%) vaccine recipients developed mild-moderate # COVID19.
Of the cases, 39/42 (92.9%) were the B.1.351 variant ā against which vaccine efficacy was 10.4%. https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1
trial in HIV(-) people in South Africa. 23/717 (3.2%) placebo & 19/750 (2.5%) vaccine recipients developed mild-moderate # COVID19. Of the cases, 39/42 (92.9%) were the B.1.351 variant ā against which vaccine efficacy was 10.4%. https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1
The authors conclude that a 2-dose regimen of ChAdOx1 did not show protection against mild-moderate #COVID19 due to B.1.351 VOC.ChAdOx1 has been shown to be effective vs. B.1.1.7 VOC in a UK study also published as a preprint.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160
Important to remember that none of these studies assessed T cell-responses.Impact of a vaccine on preventing severe disease is still what matters most.Important to monitor VOCs
but not freak out.Encourage people to get vaccinated when they get the opportunity.
